Independent of diagnosis |
Independent of diagnosis |
Independent of
diagnosis |
Independent of diagnosis |
Independent of
diagnosis |
Omeprazole |
18 |
Avoid Scheduled use for >8 weeks unless
for high- risk patients (e.g., Oral corticosteroids or chronic NSAID
use), erosive esophagitis, Barrett’s esophagitis, pathological
hypersecretory condition, or demonstrated need for maintenance treatment |
High |
Strong |
Rabeprazole |
12 |
|
|
|
Pantoprazole |
40 |
|
|
|
Prazosin |
4 |
Avoid use as an Antihypertensive |
Moderate |
Strong |
Glimepiride |
14 |
Avoid |
High |
Strong |
Human insulin, according to Random Blood Sugar |
52 |
Avoid (insulin
regimens containing only short- or rapid-acting insulin dosed according
to current blood glucose levels without concurrent use of basal or
long-acting insulin) |
Moderate |
Strong |
Nitrofurantoin |
8 |
Avoid in individuals with creatinine clearance
<30mL/min or for long- term suppression |
Low |
Strong |
Chlordiazepoxide |
3 |
Avoid |
Moderate |
Strong |
Trihexyphenidyl |
2 |
Avoid |
Moderate |
Strong |
Zolpidem |
3 |
Avoid |
Moderate |
Strong |
Clonazepam |
22 |
Avoid |
Moderate |
Strong |
Digoxin 0.25mg
|
4
|
Avoid this rate control agent as first line therapy for atrial
fibrillation Avoid as first- line therapy for heart failure. If used for
atrial fibrillation or heart failure, avoid dosages
>0.125mg/day.
|
Atrial fibrillation: low
Heart failure: low
Dosage >0.125mg/day: moderate
|
Atrial fibrillation: strong
Heart failure: strong
Dosage >0.125mg/day: strong
|
Amiodarone |
6 |
Avoid as first- line therapy for atrial fibrillation
unless the patient has heart failure or substantial left ventricular
hypertrophy |
High |
Strong |
Nortriptyline |
4 |
Avoid |
High |
Strong |
Ketorolac |
4 |
Avoid |
Moderate |
Strong |
Quetiapine |
8 |
Avoid |
Moderate |
Strong |
Clonidine |
3 |
Avoid |
Low |
Strong |
Ergot mesyloids |
2 |
Avoid |
High |
Strong |
Dependent of diagnosis |
Dependent of diagnosis |
Dependent of diagnosis |
Dependent of diagnosis |
Dependent of diagnosis |
Delirium |
|
|
|
|
Ranitidine |
3 |
Avoid |
Moderate |
Strong |
Hydrocortisone |
3 |
Avoid |
Moderate |
Strong |
Drug-drug interaction |
Drug-drug interaction |
Drug-drug interaction |
Drug-drug interaction |
Drug-drug interaction |
Prazosin + Furosemide Urinary incontinence in women |
2 |
Avoid in older
women |
Moderate |
Strong |
Hydrocortisone + ketorolac increased risk of peptic ulcer or GI bleeding |
2 |
Avoid; if not possible, provide gastrointestinal protection |
Moderate |
Strong |
Drugs that should be used with caution in older adults |
Drugs that
should be used with caution in older adults |
Drugs that should be used
with caution in older adults |
Drugs that should be used with caution in
older adults |
Drugs that should be used with caution in older
adults |
Aspirin for primary prevention of cardiovascular disease and colorectal
cancer |
12 |
Use with caution in adults ≥70 years |
Moderate |
Strong |
Furosemide |
6 |
Use with caution as they may exacerbate or cause SIADH
or hyponatremia; monitor sodium level closely when starting or changing
dosages in older adults |
Moderate |
Strong |
Torsemide |
12 |
|
|
|
Metolazone |
2 |
|
|
|
According to creatinine clearance of the patient |
According to
creatinine clearance of the patient |
According to creatinine clearance
of the patient |
According to creatinine clearance of the patient |
According to creatinine clearance of the patient |
Creatinine clearance at which action required (ml/min) |
|
|
|
|
Enoxaparin <30ml/min |
32 |
Reduced dose |
Moderate |
Strong |
Spironolactone <30ml/min |
8 |
Avoid |
Moderate |
Strong |
Ranitidine <50ml/min |
8 |
Reduced dose |
Moderate |
Strong |
Pregabalin<60ml/min |
6 |
Reduced dose |
Moderate |
Strong |
Gabapentin <60ml/min |
2 |
Reduced dose |
Moderate |
Strong |
Dabigatran <30ml/min |
4 |
Avoid; dose adjustment advised when
CrCl >30 mL/min |
Moderate |
Strong |
Trimethoprim-sulfamethoxazole <30ml/min |
3 |
Reduced dose if
CrCl 15-29ml/min Avoid if CrCl <15ml/min |
Moderate |
Strong |